such as "Introduction", "Conclusion"..etc
University of Michigan (U-M) scientists have made an important step
toward what could become the first vaccine in the U.S. to prevent
urinary tract infections, if the robust immunity achieved in mice can be
reproduced in humans.
The findings are published September 18 in the open-access journal PLoS
Urinary tract infections (UTIs) affect 53 percent of women and 14
percent of men at least once in their lives. These infections lead to
lost work time and 6.8 million medical provider's office visits, 1.3
million emergency room visits and 245,000 hospitalizations a year, with
an annual cost of $2.4 billion in the United States.
To help combat this common health issue, the U-M scientists used a
novel systematic approach, combining bioinformatics, genomics and
proteomics, to look for key parts of the bacterium, Escherichia coli,
that could be used in a vaccine to elicit an effective immune response.
The team, led by Dr. Harry L.T. Mobley, Ph.D., screened 5,379 possible
bacterial proteins and identified three strong candidates to use in a
vaccine to prime the body to fight E. coli, the cause of most
uncomplicated urinary tract infections. The vaccine prevented infection
and produced key types of immunity when tested in mice.
Scientists have attempted to develop a vaccine for UTIs over the past
two decades. This latest potential vaccine has features that may better
its chances of success. It alerts the immune system to iron receptors
on the surface of bacteria that perform a critical function allowing
infection to spread. Administered in the nose, it induces an immune
response in the body's mucosa, a first line of defense against invading
pathogens. The response, also produced in mucosal tissue in the urinary
tract, should help the body fight infection where it starts.
Mobley's team is currently testing more strains of E. coli obtained
from women treated at U-M. Most of the strains produce the same
iron-related proteins that cthe vaccine targets, an encouraging sign
that the vaccine could work against many urinary tract infections.
Mobley is seeking partners in clinical research to move the vaccine
forward into a phase 1 trial in humans. If successful, this vaccine
would take several more years to reach the market.
Enter the code exactly as it appears. All letters are case insensitive.